The board of directors of SSY Group Limited announced that the Group's Deferasirox has obtained the approval for registration from the National Medical Products Administration of China (the "NMPA") to become a bulk drug for the preparations on the market. Deferasirox is mainly used in patients with iron accumulation due to the need for long-term blood transfusions (such as thalassemia or other rare anemias patients). In addition, the Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Esmolol Hydrochloride Injection (10ml:0.1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation.

Esmolol hydrochloride Injection is mainly used in supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.